Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
Abstract People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict...
Main Authors: | Andrzej S. Januszewski, David Chen, Russell S. Scott, Rachel L. O’Connell, Nanda R. Aryal, David R. Sullivan, Gerald F. Watts, Marja-Riitta Taskinen, Philip J. Barter, James D. Best, R. John Simes, Anthony C. Keech, Alicia J. Jenkins |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-98064-y |
Similar Items
-
High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy.
by: Laxman Yetukuri, et al.
Published: (2011-01-01) -
Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome
by: Esther M.M. Ooi, et al.
Published: (2012-11-01) -
XANTHENE AND SILICON ANALOGS OF XANTHENE FLUOROPHORES AS CHEMICAL SENSORS FOR pH AND HYPOCHLOROUS ACID
by: Best, Quinn Adams
Published: (2013) -
The bioavailability of fenofibrate in rabbits
by: WANG, SHU-FANG, et al.
Published: (1992) -
The pharmacokinetics fenofibrate in rabbits
by: CHEN, YI-KAI, et al.
Published: (1992)